IP Library Granted Patent US 12,247,234
Granted Patent B2
US 12,247,234 · App. 18/059,949 · Granted Mar 11, 2025

Biocatalysts and methods for hydroxylation of chemical compounds

Inventors: Haibin Chen (Beijing, CN); Yong Koy Bong (Singapore, SG); Fabien L. Cabirol (Dusseldorf, DE); Anupam Gohel Prafulchandra (Bekasi, ID); Tao Li (Cincinnati, OH); Jeffrey C. Moore (Westfield, NJ); Martina Quintanar-Audelo (Edinburgh, GB); Yang Hong (Singapore, SG); Steven J. Collier (Concord, MA); Derek Smith (Singapore, SG)
Assignee: Codexis, Inc.
C12P17/12C12N9/0071C12P13/04C12P13/24C12P17/188C12Y114/11002Y02P20/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,247,234
App. No.
18/059,949
Filed
Nov 29, 2022
Granted
Mar 11, 2025
Kind
B2
Art Unit
1652
USPC
435/107
Abstract

The present disclosure provides engineered proline hydroxylase polypeptides for the production of hydroxylated compounds, polynucleotides encoding the engineered proline hydroxylases, host cells capable of expressing the engineered proline hydroxylases, and methods of using the engineered proline hydroxylases to prepare compounds useful in the production of active pharmaceutical agents.

Claims (28)

1. An engineered polypeptide having proline hydroxylase activity, comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO:2 and having a residue difference at residue position X25.

2. The engineered polypeptide of claim 1 , wherein the polypeptide further comprises one or more residue differences at residue positions selected from X2; X4; X5; X9; X13; X26; X29; X30; X36; X42; X52, X57; X58; X59; X66; X92; X95; X112; X115; X116; X121; X131; X150; X151; X225; X230; and X271.

3. The engineered polypeptide of claim 1 , wherein the amino acid sequence further comprises at least a combination of amino acid differences selected from:

(a) X103L and X166Q;

(b) X52P and X255Y;

(c) X4E/L/S and X115A;

(d) X25R and X58A;

(e) X29A and X166T/Q/L;

(f) X115H/D/G and X121F;

(g) X3S, X103L, and X166Q;

(h) X103L, X131Y/F, and X166T/Q/L;

(i) X26T, X103L and X166T/Q/L;

(j) X25R, X66Q, X92V and X115E;

(k) X25R, X66Q, X92V, X103L, X115E, and X166Q; and

(l) X3S, X25R, X66Q, X92V, X103L, X115E, and X166Q.

4. The engineered polypeptide of claim 1 , wherein the polypeptide further comprises one or more residue differences as compared to the sequence of SEQ ID NO: 2 at residue positions selected from: X17, X24, X26, X62, X88, X98, X114, X140, X151, X186, X188, and X205.

5. The engineered polypeptide of claim 4 , wherein the residue differences at residue positions X17, X24, X26, X62, X88, X98, X114, X140, X151, X186, X188, and X205 are selected from X17V, X24R, X24S, X26R, X26W, X62Q, X88R, X98F, X98T, X114N, X140L, XI51A, X151H, X186G, X188G, and X205V.

6. The engineered polypeptide of claim 1 , wherein the proline hydroxylase activity of the polypeptide converts substrate compound (2), (2S)-piperidine-2-carboxylic acid,

to product compound (1), (25,5S)-5-hydroxypiperidine-2-carboxylic acid,

under suitable reaction conditions.

7. The engineered polypeptide of claim 6 , wherein the proline hydroxylase activity of the polypeptide converts substrate compound (2) to product compound (1) with at least 2 fold the activity of SEQ ID NO:2, and wherein the amino acid sequence further comprises one or more residue differences selected from the group consisting of: X4Q; X4L; X51; X5L; X24S; X30P; X66Q; X86S; X92V; X113E; X115E; X150S; X166Q; X151S; X225L; and X270E.

8. The engineered polypeptide of claim 1 , wherein the proline hydroxylase activity polypeptide converts substrate compound (2) to product compound (1) in excess of product compound (1a), (2S,3R)-3-hydroxypiperidine-2-carboxylic acid,

and wherein the amino acid sequence further comprises one or more residue differences selected from the group consisting of: X115E; X131Y and X166Q.

9. The engineered polypeptide of claim 1 , wherein the polypeptide forms product compound (1),

in diastereomeric excess of product compound (1R), (25,5R)-5-hydroxypiperidine-2-carboxylic acid,

10. The engineered polypeptide of claim 1 having proline hydroxylase activity, wherein the amino acid sequence comprises a sequence selected from the group consisting of SEQ ID NO: 58 128, 132, 134, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, and 228.

11. The engineered polypeptide of claim 1 the residue difference at position X25 is X25R.

12. The engineered polypeptide of claim 2 , wherein the one or more residue differences at positions X2; X4; X5; X9; X13; X26; X29; X30; X36; X42; X52, X57; X58; X59; X66; X92; X95; X112; X115; X116; X121; X131; X150; X151; X225; X230; and X271 are selected from X2K; X2T; X4Q; X4L; X4E; X4S; X51; X5L; X5M; X91; X13T; X26T; X29A; X30V; X30P; X36T; X42E; X52P; X57T; X57A; X58A; X59G; X66Q; X86S; X92V; X95M; X112T; X112V; X113E, X115E; X115H; X115D; X115G; X115S; X115A; X116L; X121F; X131Y; X131F; X150S; X151S; X225L; X225Y; X225W; X230V; X270E; X271K; and X271R.

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (7)
Continuation 17221613 · Apr 2, 2021
Continuation 16913761 · Jun 26, 2020
Continuation 16446866 · Jun 20, 2019
Continuation 15357668 · Nov 21, 2016
Division 14399034
Provisional Application 61644135 · May 8, 2012
Related Publication 20230227875A1 · Jul 20, 2023
References Cited (128)
US 5364775A · Katsumata et al. · 1994 [cited by applicant]
US 5854040A · Ozaki et al. · 1998 [cited by applicant]
US 5962292A · Ozaki et al. · 1999 [cited by applicant]
US 5963254A · Kim et al. · 1999 [cited by applicant]
US 6117679A · Stemmer · 2000 [cited by applicant]
US 6376246B1 · Crameri et al. · 2002 [cited by applicant]
US 6537746B2 · Arnold et al. · 2003 [cited by applicant]
US 6586182B1 · Patten et al. · 2003 [cited by applicant]
US 8541209B2 · Kino et al. · 2013 [cited by applicant]
US 8883459B2 · Kino et al. · 2014 [cited by applicant]
US 9790527B2 · Chen et al. · 2017 [cited by applicant]
US 10370688B2 · Chen et al. · 2019 [cited by applicant]
US 10731189B2 · Chen et al. · 2020 [cited by applicant]
US 10995349B2 · Chen et al. · 2021 [cited by applicant]
US 11549132B2 · Chen · 2023 [cited by examiner]
US 20060195947A1 · Davis et al. · 2006 [cited by applicant]
US 20080220990A1 · Fox · 2008 [cited by applicant]
US 20090312196A1 · Colbeck et al. · 2009 [cited by applicant]
US 20110046102A1 · Ledoussal et al. · 2011 [cited by applicant]
US 20110091942A1 · Kino et al. · 2011 [cited by applicant]
US 20210230654A1 · Chen et al. · 2021 [cited by applicant]
US 20230227875A1 · Chen · 2023 [cited by examiner]
EP 0641862B1 · 2001 [cited by applicant]
EP 2290065B1 · 2014 [cited by applicant]
WO 9522625A1 · 1995 [cited by applicant]
WO 9533836A1 · 1995 [cited by applicant]
WO 9600787A1 · 1996 [cited by applicant]
WO 970078A1 · 1997 [cited by applicant]
WO 9735966A1 · 1997 [cited by applicant]
WO 9827230A1 · 1998 [cited by applicant]
WO 200042651A1 · 2000 [cited by applicant]
WO 200175767A2 · 2001 [cited by applicant]
WO 2009008908A2 · 2009 [cited by applicant]
WO 2009091856A2 · 2009 [cited by applicant]
WO 2009139365A1 · 2009 [cited by applicant]
WO 2010126820A2 · 2010 [cited by applicant]
Adams, D.R., et al., “An efficient route to the alpha-methyl ester of L-glutamic acid, and its conversion into cis-5-hydroxy-L-pipecolic acid,” Chem. Commun., 3:349-350 [1996]. [cited by applicant]
Altamura, M., et al., “2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics,” J Med Chem., 38(21):4244-56 [1995]. [cited by applicant]
Altschul, S., et al., “Basic local alignment search tool,” J. Mol. Biol., 215: 403-410 (1990). [cited by applicant]
Altschul, S.F., et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Res., 25(17):3389-3402 (1997). [cited by applicant]
Batzer, M.A., “Erratum: Structure and variability of recently inserted Alu family members”, Nucleic Acids Res 19:698-699 [1991]. [cited by applicant]
Beaucage, S.L., et al., “Deoxynucleoside phosphoamidites—A new class of key intermediates for deoxypolynucleotide synthesis,” Tetrahedron Letters, 22(20):1859-62 (1981). [cited by applicant]
Beyerman, H.C., et al., “Stereospecific synthesis and optical resolution of 5-hydroxypipecolic acid,” Recueil des Travaux Chimiques des Pays-Bas, 78(9):648-658 [1959]. [cited by applicant]
Black, M.E., et al., “Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy,” Proc Natl Acad Sci USA, 93:3525-3529 (1996). [cited by applicant]
Bolton, E.T., et al., “A General Method for the lisolation of RNA Complementary to DNA,” Proc. Natl. Acad. Sci. USA 48:1390 ( 1962). [cited by applicant]
Botman, P.N., et al., “Diastereoselective synthesis of (2S,5R)-5-hydroxypipecolic acid and 6-substituted derivatives,” Organic Letters, 6(26):4941-4944 [2004]. [cited by applicant]
Botstein, D., et al., “Strategies and applications of in vitro mutagenesis,” Science, 229(4719):1193-1201, 1985. [cited by applicant]
Breslauer, K.J., et al., “Predicting DNA duplex stability from the base sequence,” Proc. Natl. Acad. Sci. USA, 83:3746-3750 (1986). [cited by applicant]
Caldwell, R.C., et al., “Mutagenic PCR,” PCR Methods Appl., 3:S136-S140 (1994). [cited by applicant]
Callens, R.E.A., et al., “Preparation of Trans-5-Hydroxy-L-Pipecolic Acid and Cis-4-Hydroxy-L-Pipecolic Acid From L-Baikiain (1,2,5,6-L-Tetrahydropyridine-2-Carboxylic Acid),” Bulletin des Sociétés Chimiques Belges, 91(… [cited by applicant]
Carter, P., “Site-directed mutagenesis,” Biochem. J., 237:1-7 (1986). [cited by applicant]
Chen, K.X., et al., “Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles,” J Med Chem., 49(3):995-1005 [2006]. [cited by applicant]
Chen, K.X., et al., “Syntheses of novel 4-tert-alkyl ether proline-based 16- and 17-membered macrocyclic compounds,” J Org Chem., 67(8):2730-3 [2002]. [cited by applicant]
Chiou, W.H., et al., “Facile syntheses of enantiopure 3-hydroxypiperidine derivatives and 3-hydroxypipecolic acids,” J Org Chem., 75(5):1748-51 [2010]. [cited by applicant]
Christians, F.C., et al., “Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling,” Nat. Biotechnol., 17:259-264 (1999). [cited by applicant]
Clark-Lewis, J.W., et al., “Occurrence of 4-hydroxypipecolic acid in [cited by applicant]
Cohen, L.A., et al., “Synthesis of 5-Hydroxypipecolic Acid and Separation of Its Diastereoisomers,” Science, 123(3202):842-843 [1956]. [cited by applicant]
Crameri, A., et al., “DNA shuffling of a family of genes from diverse species accelerates directed evolution”, Nature, 391:288-291 (1998). [cited by applicant]
Crameri, A., et al., “Improved green fluorescent protein by molecular evolution using DNA shuffling,” Nat. Biotechnol., 14(3):315-319 (1996). [cited by applicant]
Crameri, A., et al., “Molecular evolution of an arsenate detoxification pathway by DNA shuffling,” Nat. Biotechnol., 15(5):436-438 (1997). [cited by applicant]
Dale, S.J., et al., “Oligonucleotide-directed random mutagenesis using the phosphorothioate method,” Methods Mol. Biol., 57:369-74 (1996). [cited by applicant]
De Boer, H.A., et al., “The tac promoter: A functional hybrid derived from the trp and lac promoters,” Proc. Natl Acad. Sci. USA, 80: 21-25 (1983). [cited by applicant]
Efimov, V.A., et al., “Hydroxyproline-based DNA mimics provide an efficient gene silencing in vitro and in vivo,” Nucleic Acids Res., 34(8):2247-2257 [2006]. [cited by applicant]
Eguchi, C., et al., “The novel synthesis of L-Hydroxyproline from D-Glutamic Acid,” Bull. Chem. Soc. Japan, 47(7):1704-08 [1974]. [cited by applicant]
Ermolaeva, M.D., et al., “Prediction of transcription terminators in bacterial genomes,” J. Mol. Biol., 301:27-33 [2000]. [cited by applicant]
Fasman, G.D.,CRC Practical Handbook of Biochemistry and Molecular Biology, CRC Press, Boca Raton, FL, pp. 3-70 [1989]. [cited by applicant]
Fowden, L., “Some observations on a hydroxypipecolic acid from thrift (Armeria maritima),” Biochem J., 70(4):629-33 [1958]. [cited by applicant]
Freier, S.M., et al., “Improved free-energy parameters for predictions of RNA duplex stability,” Proc. Natl. Acad. Sci USA, 83:9373-9377 (1986). [cited by applicant]
Guo, Z., et al., “3′-End-Forming Signals of Yeast mRNA,” Mol. Cell. Biol., 15(11):5983-5990 [1995]. [cited by applicant]
Hara, R., “Characterization of novel 2-oxoglutarate dependent dioxygenases converting L-proline to cis-4-hydroxy-l-proline,” Biochem Biophys Res Commun., 379(4):882-6 [2009]. [cited by applicant]
Henaut and Danchin in Neidhardt et al. [eds.], [cited by applicant]
Henikoff, S.,et al., “Amino acid substitution matrices from protein blocks,” Proc. Natl. Acad. Sci., 89:10915-10919 (1992). [cited by applicant]
Jourdant, A., et al., “An efficient stereoselective and stereodivergent synthesis of (2R,3R)- and (2R,3S)-3-hydroxypipecolic acids,” Tetrahedron Lett., 41(36):7033-7036 [2000]. [cited by applicant]
Kalamkar, N.B., et al., “Chiron approach to the synthesis of (2S,3R)-3-hydroxypipecolic acid and (2R,3R)-3-hydroxy-2-hydroxymethylpiperidine from D-glucose,” J Org Chem., 73(9):3619-22 [2008]. [cited by applicant]
Kierzek, R., et al., “Polymer-Supported RNA Synthesis and Its Application To Test the Nearest-Neighbor Model for Duplex Stability,” Biochemistry, 25:7840-7846 (1986). [cited by applicant]
Klein, C., et al., “A Simple Procedure for Selective Hydroxylation of I-Proline and I-Pipecolic Acid with Recombinantly Expressed ProlineHydroxylases,” Adv Synth. Catal., 353:1375-1383 [2011]. [cited by applicant]
Koszelewski, D., et al., “Immobilization of omega-transaminases by encapsulation in a sol-gel/celite matrix,” Journal of Molecular Catalysis B: Enzymatic, 63: 39-44 (2010). [cited by applicant]
Kramer, B., et al., “Different base/base mismatches are corrected with different efficiencies by the methyl-directed DNA mismatch-repair system of [cited by applicant]
Kumar, P., et al., “Asymmetric synthesis of both the enantiomers of trans-3-hydroxypipecolic acid,” J Org Chem., 70(1):360-3 [2005]. [cited by applicant]
Lawrence, C.C., et al., “Purification and initial characterization of proline 4-hydroxylase from Streptomyces griseoviridus P8648: a 2-oxoacid, ferrous-dependent dioxygenase involved in etamycin biosynthesis,” Biochem. … [cited by applicant]
Lee, Y.K., et al., “The novel synthesis of two diastereomers of gamma-hydroxyproline,” Bull. Chem. Soc. Japan, 46:2924-26 [1973]. [cited by applicant]
Lemire, A., et al., “Stereoselective syntheses of L-pipecolic acid and (28,3S)-3-hydroxypipecolic acid from a chiral N-imino-2-phenyl-1,2-dihydropyridine intermediate,” J Org Chem., 75(6):2077-80 [2010]. [cited by applicant]
Letavic, M.A., et al., “Synthesis and biological activity of selective pipecolic acid-based TNF-α converting enzyme (TACE) inhibitors,” Bioorg Medicinal Chem Lett., 12(10):1387-1390 [2002]. [cited by applicant]
Liang, N., et al., “Stereoselective total synthesis of cis- and trans-3-hydroxypipecolic acid,” J Org Chem., 70(24):10182-5 [2005]. [cited by applicant]
Ling, M., et al., “Approaches to DNA Mutagenesis:An Overview,” Anal. Biochem., 254:157-78 (1997). [cited by applicant]
Ma, J., et al., “Correlations between Shine-Dalgarno Sequences and Gene Features Such as Predicted Expression Levels and Operon Structures,” J Bacteriol., 184(20): 5733-5745 [2002]. [cited by applicant]
Majamaa, K., et al., “Differences between collagen hydroxylases and 2-oxoglutarate dehydrogenase in their inhibition by structural analogues of 2-oxoglutarate,” Biochem. J., 229:127-133 [1985]. [cited by applicant]
Marin, J., et al., “Synthesis of enantiopure 4-hydroxypipecolate and 4-hydroxylysine derivatives from a common 4,6-dioxopiperidinecarboxylate precursor,” J Org Chem., 69(1):130-41 [2004]. [cited by applicant]
Martin, A.R., et al., “Characterization of free and immobilized (S)-aminotransferase for acetophenone production,” Applied Microbiology and Biotechnology, 76(4): 843-851 (2007). [cited by applicant]
Mateo, C., et al., “Epoxy sepabeads: a novel epoxy support for stabilization of industrial enzymes via very intense multipoint covalent attachment,” Biotechnology Progress 18(3):629-34 (2002). [cited by applicant]
Matthes, H.W.D., et al., “Simultaneous rapid chemical synthesis of over one hundred oligonucleotides on a microscale,” EMBO J., 3(4):801-05 (1984). [cited by applicant]
McInerney, J.O., “GCUA: general codon usage analysis,” Bioinformatics, 14(4):372-73, 1998. [cited by applicant]
Minshull, J., et al., “Protein evolution by molecular breeding,” Curr. Op. Chem. Biol., 3(3):284-290 (1999). [cited by applicant]
Mori, H., et al., “Detection of Novel Proline 3-Hydroxylase Activities in [cited by applicant]
Nakamura, Y., et al., “Codon usage tabulated from international DNA sequence databases: status for the year 2000,” Nucl. Acids Res., 28:292 [2000]. [cited by applicant]
Needleman, S., et al., “A general method applicable to the search for similarities in the amino acid sequence of two proteins,” J. Mol. Biol. 48:443-453 (1970). [cited by applicant]
O'Connell, C.E., et al., “Synthesis and evaluation of some hydroxyproline-derived peptidomimetics as soprenyltransferase inhibitors” Chem Pharm Bull., 48(5):740-742 [2000]. [cited by applicant]
Pearson, W.R., “Improved tools for biological sequence comparison,” Proc. Nat'l. Acad. Sci. USA, 85:2444-2448 (1988). [cited by applicant]
Petersen, L. et al., “Novel proline hydroxylase activities in the pneumocandin-producing fungus [cited by applicant]
Ramaswarmy, S.G., et al., “One-vessel synthesis of 4-hydroxyproline from glyoxal and oxaloacetic acid,” J. Org. Chem., 42(21):3440-3443 [1977]. [cited by applicant]
Remuzon, P., “Trans-4-hydroxy-L-proline, a useful and versatile chiral starting block,” Tetrahedron, 52(44):13803-13835 [1996]. [cited by applicant]
Romanos, M.A., et al., “Foreign gene expression in yeast: a review,” Yeast 8:423-488 [1992]. [cited by applicant]
Romeo, J.T., et al., “CIs-4-Hydroxypipecolic Acid and 2,4-Cis-4,5-Trans-4,5-Dihydroxypipecolic Acid From Calliandra,” Phytochemistry 22(7):1615-1617 [1983]. [cited by applicant]
Rychlik, W., et al., “Optimization of the annealing temperature for DNA amplification in vitro,” Nucleic Acids Res, 18(21):6409-6412 (1990). [cited by applicant]
Sakai, H., et al., “Correlation between Shine-Dalgarno sequence conservation and codon usage of bacterial genes,” J. Mol. Evol. 52(2):164-170 [2001]. [cited by applicant]
Shibasaki, T., et al., “Microbial Proline 4-Hydroxylase Screening and Gene Cloning,” Appl. Environ. Microbiol, 65(9):4028-31 [1999]. [cited by applicant]
Simonen, M., et al., “Protein Secretion in [cited by applicant]
Smith, M., “In vitro mutagenesis,” Ann. Rev. Genet., 19:423-462 (1985). [cited by applicant]
Smith, T., et al., “Comparison of Biosequences,” Adv. Appl. Math, 2:482-489 (1981). [cited by applicant]
Stellwagen, E., “Dye Affinity Chromatography,” Current Protocols in Protein Science, Chapter 9, Unit 9.2-9.2.16 [2001]. [cited by applicant]
Stemmer, W., “DNA Shuffling by Random Fragmentation and Reassembly: In vitro Recombination for Molecular Evolution,” Proc. Natl. Acad. Sci. USA, 91:10747-10751 (1994). [cited by applicant]
Stemmer, W.P.C., “Rapid evolution of a protein in vitro by DNA shuffling”, Nature, 370:389-391 (1994). [cited by applicant]
Stenico, M., et al., “Codon usage in Caenorhabditis elegans: delineation of translational selection and mutational biases,” Nucl. Acids Res. 22(13):2437-46 [1994]. [cited by applicant]
Suggs, S.V., et al., “Use of synthetic oligodeoxyribonucleotides for the isolation of specific cloned DNA sequenes,” In Developmental Biology Using Purified Genes (Brown et al., eds.), pp. 683-693, Academic Press (1981). [cited by applicant]
Tiwari, S., et al., “Prediction of probable genes by Fourier analysis of genomic sequences,” Comput. Appl. Biosci. 13(3):263-270 [1997]. [cited by applicant]
Truppo, M.D., et al., “Development of an Improved Immobilized CAL-B for the Enzymatic Resolution of a Key Intermediate to Odanacatib,” Organic Process Research & Development, 15:1033-1035 (2011). [cited by applicant]
Vergnon, A.L., et al., “Solid-phase synthesis of a library of hydroxyproline derivatives,” J Comb Chem., 6(1):91-8 [2004]. [cited by applicant]
Mlla-Komaroff, L., et al., “A bacterial clone synthesizing proinsulin,” Proc. Natl Acad. Sci. USA, 75:3727-3731 (1978). [cited by applicant]
Vimberg, V., et al., “Translation initiation region sequence preferences in [cited by applicant]
Wada, K., et al., “Codon usage tabulated from the GenBank genetic sequence data,” Nucl. Acids Res., 20:2111-2118 [1992]. [cited by applicant]
Wells, J.A., et al., “Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites,” Gene, 34:315-323 (1985). [cited by applicant]
Wetmur, J. G., “DNA Probes: Applications of the Principles of Nucleic Acid Hybridization,” Crit Rev Biochem Mol Biol, 26(3/4):227-259 (1991). [cited by applicant]
Wright, F., “The ‘effective number of codons’ used in a gene,” Gene 87:23-29 [1990]. [cited by applicant]
Yaegaki, K.,et al., “Improved high-performance liquid chromatography method for quantitation of proline and hydroxyproline in biological materials,” J Chromatogr., 356(1):163-70 [1986]. [cited by applicant]
Yi, S., et al., “Covalent immobilization of omega-transaminase from Vibrio fluvialis JS17 on chitosan beads,” Process Biochemistry 42(5): 895-898 (2007). [cited by applicant]
Zhang, J-H., et al., “Directed evolution of a fucosidase from a galactosidase by DNA shuffling and screening ,” Proc. Nat. Acad. Sci., U.S.A., 94:4504-4509 (1997). [cited by applicant]
Zhao, H., et al., “Molecular evolution by staggered extension process (StEP) in vitro recombination,” Nat. Biotechnol., 16:258-261 (1998). [cited by applicant]
Gorres, K.L., et al., “Prolyl 4-hydroxylase,” Crit Rev Biochem Mol Biol., 45(2):106-124 [2010]. [cited by applicant]